A phase III, double-blind, placebo-controlled study of Vemurafenib vs. Vemurafenib plus GDC-0973 in previously untreated BRAF v600 mutation positive patients with unresectable locally advances or metastatic melanoma
|Effective start/end date||10/30/12 → 12/31/15|
- HOFFMANN-LA ROCHE PHARMACEUTICALS
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.